Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 62-70

  Tominaga, T ^a   Adachi, I ^b   Sasaki, Y ^c   Tabei, T ^d   Ikeda, T ^e   Takatsuka, Y ^f   Toi, M ^g   Suwa, T ^h   Ohashi, Y ⁱ  

^a SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f KANSAI ROSAI HOSPITAL   (Japan)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h SAITAMA RED CROSS HOSPITAL   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; Letrozole; Randomised trial

Indexed keywords

ALDOSTERONE; AMINOGLUTETHIMIDE; ANDROGEN; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CORTICOSTEROID; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; FADROZOLE; FOLLITROPIN; FORMESTANE; HYDROCORTISONE; LETROZOLE; LUTEINIZING HORMONE; MEGESTROL ACETATE; PROGESTERONE; TAMOXIFEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ALDOSTERONE BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ANOREXIA; ARTICLE; BONE DISEASE; BREAST CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GENITAL BLEEDING; HEADACHE; HEART ARREST; HORMONE DETERMINATION; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; INCREASED APPETITE; JAPAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SOFT TISSUE DISEASE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; VOMITING;

EID: 0037246562     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg014     Document Type: Article

References (28)

1. Santen RJ, Manni A, Harvey H et al. Endocrine treatment of breast cancer in women. Endocr Rev 1990; 11: 221-265.
2. Muss HB. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 1992; 21: 15-26.
3. Miller WR, Mullen P, Sourdaine P et al. Regulation of aromatase activity within the breast. J Steroid Biochem Mol Biol 1997; 61: 193-202.
4. Roseman BJ, Buzdar AU, Singletarffy SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol 1997; 66: 215-220.
5. Robustelli DCG, Pannuti F, Martoni A et al. Aminoglutethimide in advanced breast cancer: prospective, randomised comparison of two dose levels. Anticancer Res 1993; 13: 2367-2372.
6. Garcia-Giralt E, Ayme Y, Carton M et al. Second and third-line hormonotherapy in advanced postmenopausal breast cancer: a multicenter randomised trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who had become resistant to tamoxifen. Breast Cancer Res Treat 1992; 24: 139-145.
7. Höffken K, Jonat W, Possinger K et al. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 1990; 8: 875-880.
8. Harris A, Cantwell B, Carmichael J et al. Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced breast cancer. Eur J Clin Oncol 1985; 21: 1153-1158.
9. Burzar AU, Smith R, Vogel C et al. for the Multi-Institutional Trialist Collaborative Study Group. Fadrozole HC1 (CGS16949A) versus megestrol acetate in postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multi-institutional trials. Cancer 1996; 77: 2503-2513.
10. Aoyama H, Asaishi K, Abe R et al. Clinical evaluation of CGS16949A in advanced or recurrent breast cancer-a multi-institutional late phase II clinical trial. Jpn J Cancer Chemother 1994; 21: 477-484.
11. Wada T, Nomura Y, Ohashi Y et al. Late phase II study of CGS16949A, a new aromatase inhibitor-a multicentral cooperative study (Western Japan Group). Jpn J Cancer Chemother 1994; 21: 485-493.
12. Bhatnagar AS, Häusler A, Schieweck K et al. Highly selective inhibition of estrogen biosynthesis by CGS20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990; 37: 1021-1027.
13. Bhatnagar AS, Häusler A, Schieweck K. Inhibition of aromatase in vitro and in vivo by aromatase inhibitor. J Enzyme Inhib 1990; 4: 179-186.
14. Bhatnagar AS, Batzl C, Häusler A et al. Pharmacology of nonsteroidal aromatase inhibitors. In Pasqualini JR, Katzenellenbogen BS (eds): Hormone-Dependent Cancer. New York, NY: Marcel Dekker, Inc. 1989; 155-168.
15. Häusler A, Schenkel L, Krähenbühl C et al. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors. J Steroid Biochem Mol Biol 1989; 33: 125-131.
16. Iveson TJ, Smith IE, Ahern J et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS20267 in healthy postmenopausal woman. J Clin Endocrinol Metab 1993; 77: 324-331.
17. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megesterol acetate. J Clin Oncol 1998; 16: 453-461.
18. Budar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomised study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19: 3357-3366.
19. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausel women with advanced breast cancer. Ann Oncol 1998; 9: 639-645.
20. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole (Femara®) as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
21. Nomura Y, Tominaga T, Enomoto K et al. CGS20267 (letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer. Jpn J Cancer Chemother 2002; 29: 551-562.
22. Abe R, Tominaga T, Nomizu T et al. CGS20267 (letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer. (No. 1) Investigate the recommended clinical dose. Jpn J Cancer Chemother 2002; 29: 729-740.
23. Kimijima I, Tominaga T, Nomizu T et al. CGS20267 (letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer. (No. 2) Evaluation of efficacy and safety at the recommended clinical dose. Jpn J Cancer Chemother 2002; 29: 741-749.
24. The Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer. Tokyo, Japan: Kinbara-Syupan 1996; 57-68.
25. Japan Society for Cancer Therapy. General rules for recording on clinical oncology. J Jpn Soc Cancer Ther 1986; 21: 943-953.
26. Miller WR, Telford J Love RCF et al. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast 1998; 7: 273-276.
27. Geisler J, Detre S, Berntsen H et al. Influence of neoadjuvant (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230-1236.
28. Geisler J, Heynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatisation and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomised, cross-over study. J Clin Oncol 2002; 20: 751-757.